CLINICAL_TRIALS
trial_result
· 2019-12-18
Clinical Trial Update: Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder [Phase 3]
Summary
Phase 3 trial update evaluating safety, efficacy, and tolerability of vilazodone for generalized anxiety disorder has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Forest Laboratories | Conditions: Generalized Anxiety Disorder | Phase 3 | Status: COMPLETED | Results posted: 2019-12-18